SunRock Biopharma

SunRock Biopharma develops therapeutic antibodies against cancer. Currently SunRock’s efforts are concentrated into two pipelines:

• The development of therapeutic antibodies against CCR9, a novel therapeutic target expressed in T-cell Acute Lymphoblastic Leukaemia.

• The development of therapeutic antibodies against HER3, a crucial regulatory hub in many kinds of cancer, triple-negative breast cancer and colorectal cancer amongst them. This pipeline includes bispecific anti-HER3/anti-EGFR antibodies in several different formats.